Abstract
The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis.
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / therapeutic use*
-
Carbapenems / pharmacokinetics
-
Carbapenems / therapeutic use*
-
Colony Count, Microbial
-
Disease Models, Animal
-
Endocarditis, Bacterial / drug therapy*
-
Endocarditis, Bacterial / microbiology
-
Female
-
Humans
-
Methicillin Resistance*
-
Microbial Sensitivity Tests
-
Rabbits
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
-
Treatment Outcome
-
Vancomycin / pharmacokinetics
-
Vancomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
ME1036
-
Vancomycin